KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Receivables (2017 - 2025)

Bionano Genomics' Receivables history spans 7 years, with the latest figure at $4.5 million for Q3 2025.

  • For Q3 2025, Receivables fell 14.86% year-over-year to $4.5 million; the TTM value through Sep 2025 reached $4.5 million, down 14.86%, while the annual FY2024 figure was $4.9 million, 51.39% down from the prior year.
  • Receivables for Q3 2025 was $4.5 million at Bionano Genomics, up from $3.5 million in the prior quarter.
  • Across five years, Receivables topped out at $10.1 million in Q4 2023 and bottomed at $2.0 million in Q1 2021.
  • The 5-year median for Receivables is $5.3 million (2021), against an average of $5.8 million.
  • The largest annual shift saw Receivables surged 200.05% in 2022 before it tumbled 61.63% in 2025.
  • A 5-year view of Receivables shows it stood at $5.3 million in 2021, then surged by 40.88% to $7.5 million in 2022, then surged by 35.33% to $10.1 million in 2023, then crashed by 52.94% to $4.8 million in 2024, then dropped by 5.19% to $4.5 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Receivables are $4.5 million (Q3 2025), $3.5 million (Q2 2025), and $3.4 million (Q1 2025).